ME02326B - Rekonstituisani surfaktanti sa poboljšanim svojstvima - Google Patents

Rekonstituisani surfaktanti sa poboljšanim svojstvima

Info

Publication number
ME02326B
ME02326B MEP-2016-20A MEP2016A ME02326B ME 02326 B ME02326 B ME 02326B ME P2016 A MEP2016 A ME P2016A ME 02326 B ME02326 B ME 02326B
Authority
ME
Montenegro
Prior art keywords
amino acid
group
acid residue
value
integer
Prior art date
Application number
MEP-2016-20A
Other languages
English (en)
Unknown language (me)
Inventor
Per-Ola Mikael Johansson
Tore Curstedt
Bengt Robertson
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39079026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02326(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of ME02326B publication Critical patent/ME02326B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
MEP-2016-20A 2006-10-13 2007-09-28 Rekonstituisani surfaktanti sa poboljšanim svojstvima ME02326B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06021521 2006-10-13
EP07825212.9A EP2078038B1 (en) 2006-10-13 2007-09-28 Reconstituted surfactants having improved properties
PCT/IB2007/002841 WO2008044109A1 (en) 2006-10-13 2007-09-28 Reconstituted surfactants having improved properties

Publications (1)

Publication Number Publication Date
ME02326B true ME02326B (me) 2016-06-20

Family

ID=39079026

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2016-20A ME02326B (me) 2006-10-13 2007-09-28 Rekonstituisani surfaktanti sa poboljšanim svojstvima
MEP-121/09A MEP12109A (en) 2006-10-13 2007-09-28 Reconstituted surfactants having improved properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-121/09A MEP12109A (en) 2006-10-13 2007-09-28 Reconstituted surfactants having improved properties

Country Status (35)

Country Link
US (2) US8183210B2 (enExample)
EP (1) EP2078038B1 (enExample)
JP (2) JP5405307B2 (enExample)
KR (1) KR101328851B1 (enExample)
CN (2) CN103169947B (enExample)
AR (2) AR063263A1 (enExample)
AU (1) AU2007306075B2 (enExample)
BR (1) BRPI0715317B1 (enExample)
CA (1) CA2666344C (enExample)
CL (1) CL2007002931A1 (enExample)
CO (1) CO6400235A2 (enExample)
CY (1) CY1114716T1 (enExample)
DK (1) DK2078038T3 (enExample)
EA (1) EA015802B1 (enExample)
ES (1) ES2438727T3 (enExample)
GE (1) GEP20125531B (enExample)
HR (1) HRP20140052T1 (enExample)
IL (1) IL198075A (enExample)
JO (1) JO2963B1 (enExample)
MA (1) MA31062B1 (enExample)
ME (2) ME02326B (enExample)
MX (1) MX343064B (enExample)
MY (1) MY148127A (enExample)
NO (1) NO342038B1 (enExample)
NZ (1) NZ576189A (enExample)
PE (1) PE20081184A1 (enExample)
PL (1) PL2078038T3 (enExample)
PT (1) PT2078038E (enExample)
RS (1) RS53172B (enExample)
SI (1) SI2078038T1 (enExample)
TN (1) TN2009000099A1 (enExample)
TW (1) TWI388333B (enExample)
UA (1) UA94477C2 (enExample)
WO (1) WO2008044109A1 (enExample)
ZA (1) ZA200902481B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011559A2 (en) 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
CN101948526B (zh) * 2010-09-02 2012-12-05 华东理工大学 一种肺泡表面活性蛋白质(sp-b和sp-c)的分离纯化方法
EP3459556A1 (en) 2012-02-09 2019-03-27 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Synthetic analogs of lung surfactant protein sp-c and their use
US20130303726A1 (en) * 2012-04-17 2013-11-14 Chiesi Farmaceutici S.P.A. Method for the preparation of surfactant peptides
EP2922868B1 (en) * 2012-11-21 2017-09-27 Chiesi Farmaceutici S.p.A. Reconstituted pulmonary surfactants
US10717777B2 (en) 2015-12-17 2020-07-21 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Synthetic lung surfactant with enhanced stability and effectiveness
EP3452041B1 (en) 2016-03-07 2026-01-14 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for administering ppar-gamma-agonists, surfactant peptides and phospholipids
RU2748417C2 (ru) 2016-08-24 2021-05-25 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильная фармацевтическая композиция, включающая восстановленную композицию легочного сурфактанта
WO2021151853A1 (en) 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
WO2022082082A2 (en) * 2020-10-16 2022-04-21 Sherwood Russ Lehrman Lung treatment compositions
WO2025024609A1 (en) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides for lung surfactant compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US7065342B1 (en) * 1999-11-23 2006-06-20 Gofigure, L.L.C. System and mobile cellular telephone device for playing recorded music
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
WO2008011559A2 (en) * 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
EP2022798A1 (en) 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides

Also Published As

Publication number Publication date
ZA200902481B (en) 2010-07-28
AR113422A2 (es) 2020-04-29
PE20081184A1 (es) 2008-09-26
PT2078038E (pt) 2013-12-12
ES2438727T3 (es) 2014-01-20
BRPI0715317B1 (pt) 2021-10-05
MY148127A (en) 2013-02-28
AR063263A1 (es) 2009-01-14
IL198075A (en) 2016-04-21
EA015802B1 (ru) 2011-12-30
GEP20125531B (en) 2012-05-25
EP2078038A1 (en) 2009-07-15
CY1114716T1 (el) 2016-10-05
TW200824705A (en) 2008-06-16
UA94477C2 (ru) 2011-05-10
EP2078038B1 (en) 2013-11-20
CA2666344A1 (en) 2008-04-17
US8183210B2 (en) 2012-05-22
WO2008044109A1 (en) 2008-04-17
MX2009003638A (es) 2009-04-22
US20130079275A1 (en) 2013-03-28
NO342038B1 (no) 2018-03-19
TN2009000099A1 (en) 2010-08-19
SI2078038T1 (sl) 2014-02-28
MX343064B (es) 2016-10-24
IL198075A0 (en) 2011-08-01
JP5405307B2 (ja) 2014-02-05
CN103169947B (zh) 2014-10-29
CO6400235A2 (es) 2012-03-15
US20100004173A1 (en) 2010-01-07
HRP20140052T1 (hr) 2014-02-28
CN101522711B (zh) 2013-11-13
MA31062B1 (fr) 2010-01-04
CA2666344C (en) 2017-04-18
KR20090083892A (ko) 2009-08-04
US9238058B2 (en) 2016-01-19
NZ576189A (en) 2011-09-30
EA200900373A1 (ru) 2009-10-30
JP2013241449A (ja) 2013-12-05
RS53172B (sr) 2014-06-30
TWI388333B (zh) 2013-03-11
NO20091441L (no) 2009-06-23
PL2078038T3 (pl) 2014-05-30
CN101522711A (zh) 2009-09-02
MEP12109A (en) 2011-12-20
CL2007002931A1 (es) 2008-03-24
HK1134497A1 (en) 2010-04-30
BRPI0715317A2 (pt) 2013-07-09
JO2963B1 (en) 2016-03-15
KR101328851B1 (ko) 2013-11-14
AU2007306075B2 (en) 2012-08-09
JP2010505937A (ja) 2010-02-25
CN103169947A (zh) 2013-06-26
AU2007306075A1 (en) 2008-04-17
DK2078038T3 (da) 2013-12-02
HK1185274A1 (en) 2014-02-14

Similar Documents

Publication Publication Date Title
JP2018505146A5 (enExample)
CO5400118A1 (es) Composiciones detergentes humectantes
AR063263A1 (es) Agentes tensioactivos reconstituidos
RU2219941C2 (ru) Агонисты аполипопротеина а-1 и их применение для лечения заболеваний, связанных с дислипидемией
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ATE509618T1 (de) Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
DE60119145D1 (de) Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
HRP20191292T1 (hr) Derivati fgf21 i njihova upotreba
ATE445331T1 (de) Canolaproteinisolat funktionalität iii
JP2002541233A5 (enExample)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2013543497A5 (enExample)
EA201070105A1 (ru) Композиции антител
EA200701274A1 (ru) Нанодисперсные составы на основе такролимуса
HRP20120310T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
MA29416B1 (fr) Inhibiteurs d'age
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
EA201992226A1 (ru) Агонисты npra, композиции и их использование
AR073573A1 (es) Metodos para utilizar composiciones de aminopiridina de liberacion sostenida
WO2008078102A3 (en) Lipids and their use as non-viral delivery vehicle
MX2009002962A (es) Peptidos antibacterianos y antivirales de actinomadura namibiensis.
EA200100906A1 (ru) Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких
BR0117191A (pt) Composições nanoparticuladas de isotretinoina
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.